The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit

American Journal of Hematology

Volumn 90, Issue 5, 2015, Pages E86-E91

  Harrison, Simon J ^a,b   Quach, Hang ^c   Link, Emma ^a   Feng, Huaibao ^d   Dean, Joanne ^a   Copeman, Michael ^e   Van De Velde, Helgi ^f   Schwarer, Anthony ^g   Baker, Bartrum ^h   Spencer, Andrew ⁱ   Catalano, John ^j   Campbell, Philip ^k   Augustson, Bradley ^l   Romeril, Ken ^m   Prince, Henry Miles ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d Janssen Research and Development   (United States)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^g BOX HILL HOSPITAL   (Australia)

^h PALMERSTON NORTH HOSPITAL   (New Zealand)

ⁱ ALFRED HOSPITAL   (Australia)

^j FRANKSTON HOSPITAL   (Australia)

^k GEELONG HOSPITAL   (Australia)

^l SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^m WELLINGTON HOSPITAL   (New Zealand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; HEMOGLOBIN; IMMUNOGLOBULIN; VALACICLOVIR; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; COHORT ANALYSIS; CREATININE CLEARANCE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; KARNOFSKY PERFORMANCE STATUS; KIDNEY FAILURE; LUNG EMBOLISM; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REINFECTION; REMISSION; SENSORY NEUROPATHY; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS REACTIVATION; WEIGHT CHANGE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG MONITORING; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RECURRENT DISEASE; RISK; SURVIVAL; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; ODDS RATIO; PROSPECTIVE STUDIES; PYRAZINES; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928242073     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23967     Document Type: Article

References (33)

1. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-2526.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-2520.
3. Kikuchi J, Wada T, Shimizu R, et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 2010;116:406-417.
4. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
5. Horton TM, Plon SE, Blaney SM, et al. Synergistic cytotoxicity of bortezomib (formerly PS-341) and dexamethasone in acute lymphoblastic leukemia. Blood 2003;102:3207a.
6. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-3076.
7. Rosinol L, Oriol A, Mateos MV, et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: Efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007;25:4452-4458.
8. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
9. Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006;106:1316-1319.
10. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929-934.
11. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.
12. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431-440.
13. Kropff MH, Bisping G, Wenning D, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 2005;29:587-590.
14. Yuan ZG, Jin J, Huang XJ, et al. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: An open-label, observational, multi-center study in china. Chin Med J 2011;124:2969-2974.
15. Dimopoulos MA, Beksac M, Benboubker L, et al. Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica 2013;98:1264-1272.
16. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770-1781.
17. Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma IX results and meta-analysis. Blood 2012;119:7-15.
18. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009;27:1788-1793.
19. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012;119:940-948.
20. Mateos MV, Oriol A, Martinez-Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial. Lancet Oncol 2010;11:934-941.
21. Niesvizky R, Flinn IW, Rifkin RM, et al. Phase 3b UPFRONT study: Safety and efficacy of weekly bortezomib maintenance therapy after Bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma Patients. ASH Annual Meeting Abstracts 2010;116:619.
22. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30:2946-2955.
23. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European group for blood and marrow Transplant. Br J Haematol 1998;102:1115-1123.
24. 24. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the international myeloma workshop consensus panel 1. Blood 2011;117:4691-4695. [PMC][10.1182/blood-2010-10-299487] [21292775]24.
25. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012;119:4391-4394.
26. Khan ML, Reeder CB, Kumar SK, et al. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol 2012;156:326-333.
27. Corso A, Varettoni M, Mangiacavalli S, et al. Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived. Eur J Haematol 2009;83:449-454.
28. Igarashi N, Chou T, Hirose T, et al. Bortezomib and dexamethasone for japanese patients with relapsed and refractory multiple myeloma: A single center experience. Int J Hematol 2010;92:518-523.
29. Kobayashi T, Kuroda J, Shimura K, et al. Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: The collaborative study at six institutes in kyoto and osaka. Int J Hematol 2010;92:579-586.
30. Chauhan D, Li G, Auclair D, et al. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood 2003;101:3606-3614.
31. Quach H, Mileshkin L, Seymour JF, et al. Predicting durable remissions following thalidomide therapy for relapsed myeloma. Leuk Lymph 2009;50:223-229.
32. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
33. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22-32.